Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 2 Pilot Study Evaluating the Activity and Safety of FP 1039 in Subjects With Advanced and/or Recurrent Endometrial Cancers With Specific FGFR2 Mutations

NCT01244438 is registered in ClinicalTrials.gov with Five Prime Therapeutics, Inc. as lead sponsor.

NCT NCT01244438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01244438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 2 Pilot Study Evaluating the Activity and Safety of FP 1039 in Subjects With Advanced and/or Recurrent Endometrial Cancers With Specific FGFR2 Mutations
Lead sponsor
Five Prime Therapeutics, Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
January 31, 2011
Completion date
December 31, 2012
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancers with fgfr2 mutations